Study on Raludotatug Deruxtecan for Treating Ovarian Cancer

Inclusion Criteria

• Diagnosed with high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
• Have measurable cancer based on specific medical criteria.
• For some participants: Cancer has returned after 1 to 3 previous treatments and has shown signs of growth at least 6 months after the last platinum-based treatment (platinum-sensitive).
• For other participants: Cancer has returned after 1 to 3 previous treatments and has shown signs of growth less than 6 months after the last platinum-based treatment (platinum-resistant).
• Eligible for treatment with bevacizumab.
• Provided a tumor sample from a biopsy.
• In good general health with a performance status score of 0 or 1.
• If HIV-positive, must have well-controlled HIV with medication.
• If hepatitis B positive, must have been treated for at least 4 weeks and have no detectable virus.
• If previously infected with hepatitis C, must have no detectable virus at screening.

Exclusion Criteria

• Had a stroke, mini-stroke, or other serious blood clot event in the past 6 months.
• Have uncontrolled or serious heart disease.
• Have severe lung problems from other illnesses or conditions.
• Have significant nerve damage (Grade 2 or higher).
• Have been treated with cadherin-6-targeted drugs before.
• Have had cancer treatment, including experimental drugs, within 4 weeks or 5 half-lives before starting the study.
• Have had radiation therapy within 2 weeks before starting the study or have side effects from radiation needing steroids.
• Are on long-term steroid treatment.
• Have another active cancer that is growing or needed treatment in the past 3 years.
• Have active cancer spread to the brain or spinal cord.
• Have a history of lung inflammation needing steroids or current lung inflammation.
• Have an active infection needing treatment.
• If HIV-positive, have a history of Kaposi's sarcoma or Multicentric Castleman's Disease.